Kim, H.S.; Nakagawa, K.; Akahori, T.; Nakamura, K.; Takagi, T.; Sho, M.; Park, J.S.; Yoon, D.S.
Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma? J. Clin. Med. 2021, 10, 873.
https://doi.org/10.3390/jcm10040873
AMA Style
Kim HS, Nakagawa K, Akahori T, Nakamura K, Takagi T, Sho M, Park JS, Yoon DS.
Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma? Journal of Clinical Medicine. 2021; 10(4):873.
https://doi.org/10.3390/jcm10040873
Chicago/Turabian Style
Kim, Hyung Sun, Kenji Nakagawa, Takahiro Akahori, Kota Nakamura, Tadataka Takagi, Masayuki Sho, Joon Seong Park, and Dong Sup Yoon.
2021. "Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?" Journal of Clinical Medicine 10, no. 4: 873.
https://doi.org/10.3390/jcm10040873
APA Style
Kim, H. S., Nakagawa, K., Akahori, T., Nakamura, K., Takagi, T., Sho, M., Park, J. S., & Yoon, D. S.
(2021). Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma? Journal of Clinical Medicine, 10(4), 873.
https://doi.org/10.3390/jcm10040873